OpenURL Connection Search

Select item for more details and to access through your institution.

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies.
Published in:
Open Forum Infectious Diseases, 2019, v. 6, p. S865, doi. 10.1093/ofid/ofz360.2173
By:
- Patel, Parul;
- Ford, Susan L;
- Crauwels, Herta;
- Han, Kelong;
- Rossenu, Stefaan;
- Neyens, Martine;
- Griffith, Sandy;
- Hudson, Krischan J;
- Margolis, David;
- Baker, Mark;
- Williams, Peter;
- Spreen, William
Publication type:
Article
884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.
Published in:
Open Forum Infectious Diseases, 2019, v. 6, p. S20, doi. 10.1093/ofid/ofz359.043
By:
- Teichner, Paula;
- Cutrell, Amy;
- D'Amico, Ronald;
- Dorey, David;
- Griffith, Sandy;
- Harrington, Conn M;
- Huang, Jenny;
- Hudson, Krischan J;
- Margolis, David;
- Mrus, Joseph;
- Polli, Joseph;
- Spreen, William;
- Williams, Peter;
- Solingen-Ristea, Rodica Van;
- Shaefer, Mark S
Publication type:
Article
Distinct mechanisms of integrin binding by Yersinia pseudotuberculosis adhesins determine the phagocytic response of host macrophages.
Published in:
Cellular Microbiology, 2005, v. 7, n. 10, p. 1474, doi. 10.1111/j.1462-5822.2005.00571.x
By:
- Hudson, Krischan J.;
- Bliska, James B.;
- Bouton, Amy H.
Publication type:
Article
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Published in:
Patient, 2021, v. 14, n. 6, p. 849, doi. 10.1007/s40271-021-00524-0
By:
- Chounta, Vasiliki;
- Overton, Edgar T.;
- Mills, Anthony;
- Swindells, Susan;
- Benn, Paul D.;
- Vanveggel, Simon;
- van Solingen-Ristea, Rodica;
- Wang, Yuanyuan;
- Hudson, Krischan J.;
- Shaefer, Mark S.;
- Margolis, David A.;
- Smith, Kimberly Y.;
- Spreen, William R.
Publication type:
Article
Cabotegravir + Rilpivirine Every 2 Months Is Noninferior To Monthly: ATLAS-2M Study.
Published in:
Infection & Chemotherapy, 2020, v. 52, p. S378
By:
- Overton, Edgar T.;
- Richmond, Gary;
- Rizzardini, Giuliano;
- Jaeger, Hans;
- Orrell, Catherine;
- Nagimova6, Firaya;
- Bredeek, Fritz;
- del Toro, Miguel García;
- Benn, Paul D.;
- Yuanyuan Wang;
- Hudson, Krischan J.;
- Margolis, David A.;
- Smith, Kimberly;
- Williams, Peter E.;
- Spreen, William;
- Yeon Sook Kim
Publication type:
Article

Found: 5

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies.

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.

Distinct mechanisms of integrin binding by Yersinia pseudotuberculosis adhesins determine the phagocytic response of host macrophages.

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

Cabotegravir + Rilpivirine Every 2 Months Is Noninferior To Monthly: ATLAS-2M Study.